Bausch & Lomb PureVision 30-Day Indication Receives FDA Go-Ahead
This article was originally published in The Gray Sheet
Executive Summary
A hearing to address patent infringement allegations by Bausch & Lomb over Ciba Vision's extended-wear contact lenses will take place in January in Rochester, New York federal court, according to B&L
You may also be interested in...
B&L Relying On PureVision Growth To Offset Refractive Market Decline
Bausch & Lomb says it is counting on product introductions that incorporate new technologies, such as the PureVision continuous-wear lenses, to offset lagging sales of older lines as the firm works to stabilize its financial performance
B&L Relying On PureVision Growth To Offset Refractive Market Decline
Bausch & Lomb says it is counting on product introductions that incorporate new technologies, such as the PureVision continuous-wear lenses, to offset lagging sales of older lines as the firm works to stabilize its financial performance
Ciba Vision's Focus
Extended-wear, disposable Focus Night & Day soft contact lenses will be priced "competitively" with the cost of wearing and cleaning ordinary disposables, the Novartis unit says following FDA approval Oct. 12. The lenses are the first to be approved for continuous 30-day wear, as opposed to the conventional seven-day maximum. Made of lotrafilcon A, the Focus is available for eyes +0.25 diopters to +6 D in 0.25 D increments, -0.25 D to -8 D eyes in 0.25 D steps and -8.5 D to -10 D eyes in 0.5 D steps. FDA's Ophthalmic Devices Panel recommended approval in July (1"The Gray Sheet" July 23, 2001, p. 27). A required postmarket study will evaluate long-term risk of infection